American Academy of Neurology

From Wikipedia, the free encyclopedia
Jump to: navigation, search

The American Academy of Neurology (AAN) is a professional society representing more than 21,000 neurologists and neuroscientists.[1] As a medical specialty society it was established in 1948 by A.B. Baker of the University of Minnesota to advance the art and science of neurology, and thereby promote the best possible care for patients with neurological disorders. It is currently based in Minneapolis, Minnesota.

Activities[edit]

In April 2012, the academy relocated its headquarters to a new 63,000-square-foot building in downtown Minneapolis.[2] The five-story facility cost $20 million to build.[2]

The American Academy of Neurology has formal policies for avoiding conflicts of interest with pharmaceutical and device industries, and meets or exceeds all recommendations of the Council of Medical Specialty Societies Code.[3]

Annual meeting[edit]

The annual meeting of the AAN is attended by more than 15,000 neurologists and neuroscientists from the US and abroad. The 2011 meeting was in Honolulu, featuring scientific presentations and educational courses. Plenary presentations on three days will highlight cutting edge clinical, translational and basic research. The annual "Future of Neuroscience" conference will highlight advances in the Alzheimer Disease Neuroimaging (ADNI) project.[4]

Top five Choosing Wisely® recommendations[edit]

The AAN partnered with the American Board of Internal Medicine Foundation and Consumer Reports to provide their top 5 recommendations for neurologists. Out of 178 nominations from AAN members, these 5 guidelines were selected by a panel of 4 AAN Staff and 10 experienced AAN members who voted according to a modified Delphi method.<[5]> The guidelines were published in Neurology on February 20, 2013.

  1. Don’t perform EEGs for headaches.
  2. Don’t perform imaging of the carotid arteries for simple syncope without other neurologic symptoms.
  3. Don’t use opioid or butalbital treatment for migraine except as a last resort.
  4. Don’t prescribe interferon-beta or glatiramer acetate to patients with disability from progressive, non-relapsing forms of multiple sclerosis.
  5. Don’t recommend CEA for asymptomatic carotid stenosis unless the complication rate is low (<3%).

Publications[edit]

AAN publishes the following journal:

See also[edit]

References[edit]

  1. ^ "American Academy of Neurology". Neurology Today. Retrieved 4 July 2012. 
  2. ^ a b Don Jacobson (June 28, 2012). "Academy of Neurology strikes right balance in its new home". The Star Tribune. Retrieved 3 July 2012. 
  3. ^ Hutchins, J. C.; Rydell, C. M.; Griggs, R. C.; Sagsveen, M.; Bernat, J. L.; American Academy of Neurology Pharmaceutical Device Industry Conflict of Interest Task Force (2012). "American Academy of Neurology policy on pharmaceutical and device industry support". Neurology 78 (10): 750–754. doi:10.1212/WNL.0b013e318248e4ff. PMID 22391605.  edit
  4. ^ "Science at the AAN Annual Meeting". American Academy of Neurology. Retrieved 4 July 2012. 
  5. ^ Mattson, D. H.; Lisak, R. P.; Jones, D. E.; Corboy, J. R.; Larson, R.; Gronseth, G.; Getchius, T. S. D.; Langer-Gould, A.; Langer-Gould, A. M.; Gronseth, G. S.; Larson, R.; Getchius, T. S. D. (2013). "The American Academy of Neurology's Top Five Choosing Wisely recommendations". Neurology 81 (11): 1022–1023. doi:10.1212/WNL.0b013e3182a69c98. PMID 24019388.  edit

External links[edit]